Atara Biotherapeutics, Inc.（ATRA）の財務ATRAAtara Biotherapeutics, Inc.

Evaluating the bottom line, Atara Biotherapeutics, Inc. maintains a gross margin of 69.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -627.46%, while the net margin is -767.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ATRA converts its operational activities into shareholder value.

In the context of the broader market, ATRA competes directly with industry leaders such as CRBP and TNYA. With a market capitalization of $79.92M, it holds a leading position in the sector. When comparing efficiency, ATRA's gross margin of 69.68% stands against CRBP's N/A and TNYA's N/A. Such benchmarking helps identify whether Atara Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Atara Biotherapeutics has shown fluctuating financial performance, with a gross margin of 69.68% in Q2 2026, but a negative net income margin of -767.30%. The company reported a significant drop in revenue from $98.15 million in Q1 2025 to just $630,000 in Q2 2026, indicating severe financial distress.